Entrada Therapeutics, Inc.
TRDANext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for TRDA. That does not mean none is planned.
Get an email about TRDA's next catalysts
Track Entrada Therapeutics (TRDA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
ENTR-601-44
Duchenne Muscular Dystrophy (DMD)
ENTR-601-45
Duchenne Muscular Dystrophy (DMD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ENTR-601-44 | Phase 2 | Duchenne Muscular Dystrophy (DMD) | - | - |
ENTR-601-45 | Phase 2 | Duchenne Muscular Dystrophy (DMD) | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Entrada Therapeutics, Inc.'s drug pipeline?β
CatalystAlert tracks 2 drug candidates in Entrada Therapeutics, Inc.'s (TRDA) pipeline across Phase 2. Its lead program is ENTR-601-44 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Entrada Therapeutics, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Entrada Therapeutics, Inc. (TRDA) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track TRDA biotech catalysts?β
Add TRDA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Entrada Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
